Comparative Effectiveness and Harms of Belatacept vs. Tacrolimus Among Kidney Transplant Recipients (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1213; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "There was no evidence of difference in cardiac ischemic events or mortality between the two groups (Table 1). Conclusion Our findings provide real-world evidence on the comparative effectiveness and harms of belatacept versus tacrolimus initiation among kidney transplant recipients and may i nform clinician-patient shared decision-making when selecting maintenance immunosuppression."
Clinical • HEOR • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Myocardial Ischemia • Transplantation
|
|
Sherin Ismail; Michele Jonsson Funk; Jennifer E. Flythe; Jessie K. Edwards; Til Stürmer; Elizabeth Kotzen; Evan Mayo-Wilson
|